← Back to Companies

Invivyd

Biopharmaceutical company developing antibody-based therapies to protect against evolving viral infectious diseases, including COVID-19 and influenza.

Location
New Haven, Connecticut, USA
Founded
2020
Categories
biotech, antibody-therapeutics, infectious-disease, covid-19, influenza

Notes

Invivyd (formerly Adagio Therapeutics) is a biopharmaceutical company focused on developing antibody-based therapies to address evolving viral threats. The company combines advanced viral surveillance and predictive modeling with antibody engineering to develop potent therapeutics resistant to viral evolution.

Invivyd's proprietary platform enables rapid identification and engineering of antibodies that can neutralize current and emerging viral variants. The company's initial focus has been on COVID-19, with expansion into influenza and other high-need infectious disease indications.

Team

  • David Hering - Chief Executive Officer
  • Robert Allen, Ph.D. - Chief Scientific Officer
  • William Duke, MBA - Chief Financial Officer
  • Jill Andersen, J.D. - Chief Legal Officer & Corporate Secretary
  • Mark Wingertzahn, Ph.D. - Senior Vice President, Clinical Development
  • Timothy Lee - Chief Commercial Officer
  • Julie Green, MBA - Chief Human Resources Officer
  • Rachael Gerlach, Ph.D. - Senior Vice President, Regulatory Affairs
  • Tillman Gerngross, Ph.D. - Co-founder & Board Member

Additional Research Findings

  • In Bain Capital Life Sciences portfolio
  • Originally founded as Adagio Therapeutics in 2020
  • Proprietary viral surveillance and antibody engineering platform
  • Focus on COVID-19 and influenza antibody therapeutics
  • Designed antibodies to be resistant to viral evolution
  • Headquartered at 209 Church Street, New Haven, CT 06510
  • Expanding pipeline to address multiple infectious disease indications

Sources